Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998793 | 0.88 | SLC6A2 (0.34) | SLC6A3SLC6A2SLC6A4KMT2ANPSR1 | |
| SCHEMBL5998867 | 0.83 | NPC1 (0.35) | SLC6A3TNFSLC6A2SLC6A4NPC1 | |
| SCHEMBL5997427 | 0.81 | MEN1 (0.34) | NPC1RAB9AKMT2AHTR2AHTR2C | |
| SCHEMBL5998282 | 0.81 | HSD17B3 (0.38) | TNFNPC1RAB9AKMT2AHSD17B3 | |
| SCHEMBL5997031 | 0.81 | DPP9 (0.36) | NPC1RAB9AHSD17B3 | |
| SCHEMBL5998849 | 0.79 | HDAC4 (0.36) | TNFNPC1RAB9AKMT2A | |
| SCHEMBL5996077 | 0.75 | SLC6A3 (0.32) | SLC6A3TNFSLC6A2SLC6A4HTR2A | |
| SCHEMBL5998512 | 0.74 | GABRG2 (0.39) | KMT2AHSD17B3 | |
| SCHEMBL5998668 | 0.72 | ALDH1A1 (0.37) | NPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL5997296 | 0.72 | CRBN (0.36) | NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094908-B2 | Reduction of carbonyl compounds using the carbonyl reductase of Kluyveromyces marxianus | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2006-08-22 | — | — | US | disclosed |
| US-20030139464-A1 | Reduction of carbonyl compounds using the carbonyl reductase of kluyveromyces marxianus | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139464-A1 | Reduction of carbonyl compounds using the carbonyl reductase of kluyveromyces marxianus | CBR1, CBR3, DCXR | SLC6A3 4798/4885TNF 2425/4885SLC6A2 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.